The CONSORTiUM-IO study was a first-in-human, open-label phase 1 trial assessing the safety and early efficacy signal of the bacterial consortium VE800 administered with nivolumab. The trial enrolled three discrete cohorts: patients with PD-1–refractory melanoma, PD-1–naive gastric/gastroesophageal junction adenocarcinoma (G/GEJ), and PD-1–naive microsatellite-stable colorectal cancer (MSS CRC). The source reported that VE800 comprises 11 commensal bacterial strains derived from healthy donors and maintained in clonal cell banks to reduce batch variability and the pathogen transmission risks seen with fecal microbiota transplantation (FMT). The protocol was multicenter, conducted under Good Clinical Practice, and registered as NCT04208958.
Investigators reported that the combination of VE800 plus nivolumab was well tolerated across the enrolled cohorts. The abstract did not list specific adverse event rates or grades in the text provided; those granular safety details were not reported in the source excerpt. Still, the study team observed no unexpected toxicity signals attributable to the bacterial consortium during this phase 1 evaluation. Ethics and oversight were documented: the protocol and informed consent forms received institutional review board approval at multiple participating sites, and all patients provided written informed consent.
Authors concluded that adding VE800 to anti–PD-1 therapy with nivolumab did not yield improvements over historic response rates for the targeted indications. The source described the combination as offering no improvement relative to expected outcomes in these patient populations. The report framed these efficacy outcomes as the primary negative signal of the study: tolerability without a population-level enhancement in antitumor response when benchmarked against historical data. The source did not report specific response-rate numbers or comparative statistics in the abstract text provided; therefore such numerical details are not restated here.
In exploratory analyses limited to the melanoma cohort, the study team observed that engraftment of VE800 strains correlated with longer progression-free survival (PFS) and with increased measures of peripheral immune activation. These associations were described as exploratory by the authors; the source did not present detailed methods, effect sizes, or statistical parameters in the abstract excerpt. Investigators assessed strain presence using genomic assignments referenced to the Genome Taxonomy Database Version 207, and sequencing data supporting strain detection were deposited under the stated BioProject accessions. The authors suggested that strain-level engraftment could be mechanistically relevant to individual patient benefit, but they did not claim definitive efficacy based on these exploratory signals.
The study made several data resources available: VE800 strain genomes and metagenomic sequencing data are deposited under the BioProject accessions cited in the source, and other raw analysis data appear in supplementary tables. The source stated that additional materials will be shared under a material transfer agreement with Vedanta Biosciences. Multiple authors are employees or advisors of Vedanta Biosciences and hold equity; Vedanta holds patents related to the compositions and methods referenced by the authors. The source lists competing interests and patents and confirms the authors vouch for data accuracy and completeness.
The study team reported clear limitations within the submitted material. The combination was tolerable but did not improve outcomes over historic controls; that negative primary signal limits claims of clinical benefit at the cohort level. The engraftment–PFS relationship in melanoma was exploratory and thus hypothesis-generating rather than confirmatory. The abstract did not provide detailed adverse-event tables, response-rate numerators or denominators, or dosing and schedule details for VE800 administration; those specifics were not reported in the excerpt and therefore are not described here. The source indicates where sequencing and supplemental data are available, but broader questions remain: whether particular strains drive the observed associations, how engraftment durability affects outcomes, and whether optimized patient selection or combination strategies could alter efficacy. These questions, along with next steps for regulatory review or subsequent trials, were not specified in the provided text and therefore remain open based on the authors' reporting.